Akan Yaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Akan Yaman has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Kandemir
Department of Pediatrics, Istanbul Health and Technology University, Istanbul 34275, Turkey
8 shared publications - Sinem Gülcan Kersin
Marmara University
5 shared publications - Zeynep Alp Ünkar
Department of Pediatrics, Division of Neonatology, Faculty of Medicine, İstanbul University-Cerrahpasa, İstanbul, Türkiye
4 shared publications - Asli Memisoglu
Marmara University
3 shared publications - Hülya Selva Bilgen
Marmara University
3 shared publications - Mehmet Tolga Köle
Ankara Etlik Şehir Hastanesi
3 shared publications
Latest Publications
- Open Access
- 16 September 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (5) , 939-945
Ultrasound-derived reference values for neonatal liver and spleen dimensions: a retrospective cohort study
Aims: To determine liver and spleen sizes in preterm and term neonates using ultrasonography during the first week of life, and to examine their associations with gestational age, birth weight, length, gender, and postmenstrual week. Methods: In this retrospective study, 112 neonates (66 preterm, 46 term) admitted to a tertiary NICU between June and December 2020 were included. Only infants with normal liver function and without conditions affecting organ size were analyzed. Liver and spleen dimensions were measured by ultrasonography within the first seven postnatal days. Correlations were assessed using Pearson, Bayesian Kendall’s, and Bayesian Pearson tests. Regression analyses and comparisons with published data were also performed. Results: In preterm infants, liver size correlated strongly with gestational age (r=0.825) and spleen size with birth weight (r=0.777). In term infants, liver size correlated with birth length (r=0.491) and spleen size with birth weight (r=0.495). Each 1-week increase in gestational age was associated with a 1.8 mm increase in liver size in preterm infants, while each 100 g increase in birth weight increased spleen size by 0.8 mm in both groups. Conclusion: Liver and spleen sizes are closely linked to gestational age, birth weight, and length in neonates. Population-specific percentile references are recommended to improve clinical assessment accuracy.
- 16 September 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (5) , 939-945
Open AccessUltrasound-derived reference values for neonatal liver and spleen dimensions: a retrospective cohort study
Aims: To determine liver and spleen sizes in preterm and term neonates using ultrasonography during the first week of life, and to examine their associations with gestational age, birth weight, length, gender, and postmenstrual week. Methods: In this retrospective study, 112 neonates (66 preterm, 46 term) admitted to a tertiary NICU between June and December 2020 were included. Only infants with normal liver function and without conditions affecting organ size were analyzed. Liver and spleen dimensions were measured by ultrasonography within the first seven postnatal days. Correlations were assessed using Pearson, Bayesian Kendall’s, and Bayesian Pearson tests. Regression analyses and comparisons with published data were also performed. Results: In preterm infants, liver size correlated strongly with gestational age (r=0.825) and spleen size with birth weight (r=0.777). In term infants, liver size correlated with birth length (r=0.491) and spleen size with birth weight (r=0.495). Each 1-week increase in gestational age was associated with a 1.8 mm increase in liver size in preterm infants, while each 100 g increase in birth weight increased spleen size by 0.8 mm in both groups. Conclusion: Liver and spleen sizes are closely linked to gestational age, birth weight, and length in neonates. Population-specific percentile references are recommended to improve clinical assessment accuracy.
- Open Access
- 15 October 2024
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 35 (1)
Early Period Survival and Neurologic Prognosis in Newborns with Perinatal Asphyxia: A Tertiary Center Experience and a Mortality Chart
Background: Clinicians require more data regarding mortality and brain damage risk factors in perinatal asphyxia. Objectives: To assess early term outcomes and identify mortality risk factors in perinatal asphyxia. Methods: This study was conducted in a referral-center tertiary intensive care unit in Istanbul, Turkey, between 2016 and 2023. We included all patients who underwent therapeutic hypothermia treatment due to perinatal asphyxia. We recorded laboratory follow-up data, magnetic resonance imaging (MRI) findings, amplitude-integrated electroencephalograms (aEEG) results, mortality, and clinical outcomes. Both conventional frequentist statistical methods and Bayesian methods were used for analysis. Results: A total of 164 patients were included in the study, with an overall mortality rate of 9.8%. Risk factors for mortality included LDH, troponin I, INR, lactate, 2nd day creatinine, voltage anomalies, seizures, and male gender, as well as APGAR scores. A basic chart for mortality prediction was developed. The Sarnat score showed strong evidence, and APGAR 1 showed anecdotal evidence for association with brain damage, although brain damage was independent of laboratory results and other clinical findings, based on moderate and anecdotal evidence from Bayesian calculations. Cranial MRI findings revealed profound damage in 14.8% of Sarnat 1, 21.8% of Sarnat 2, and 50% of Sarnat 3 patients. Conclusions: This study presents prognostic factors for survival and brain damage in perinatal asphyxia. We recommend obtaining cranial MRI for all patients diagnosed with asphyxia, as most laboratory tests were independent of brain damage. Given that profound brain damage can occur even in Sarnat stage I patients, we emphasize the importance of therapeutic hypothermia for these patients.
- 15 October 2024
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 35 (1)
Open AccessEarly Period Survival and Neurologic Prognosis in Newborns with Perinatal Asphyxia: A Tertiary Center Experience and a Mortality Chart
Background: Clinicians require more data regarding mortality and brain damage risk factors in perinatal asphyxia. Objectives: To assess early term outcomes and identify mortality risk factors in perinatal asphyxia. Methods: This study was conducted in a referral-center tertiary intensive care unit in Istanbul, Turkey, between 2016 and 2023. We included all patients who underwent therapeutic hypothermia treatment due to perinatal asphyxia. We recorded laboratory follow-up data, magnetic resonance imaging (MRI) findings, amplitude-integrated electroencephalograms (aEEG) results, mortality, and clinical outcomes. Both conventional frequentist statistical methods and Bayesian methods were used for analysis. Results: A total of 164 patients were included in the study, with an overall mortality rate of 9.8%. Risk factors for mortality included LDH, troponin I, INR, lactate, 2nd day creatinine, voltage anomalies, seizures, and male gender, as well as APGAR scores. A basic chart for mortality prediction was developed. The Sarnat score showed strong evidence, and APGAR 1 showed anecdotal evidence for association with brain damage, although brain damage was independent of laboratory results and other clinical findings, based on moderate and anecdotal evidence from Bayesian calculations. Cranial MRI findings revealed profound damage in 14.8% of Sarnat 1, 21.8% of Sarnat 2, and 50% of Sarnat 3 patients. Conclusions: This study presents prognostic factors for survival and brain damage in perinatal asphyxia. We recommend obtaining cranial MRI for all patients diagnosed with asphyxia, as most laboratory tests were independent of brain damage. Given that profound brain damage can occur even in Sarnat stage I patients, we emphasize the importance of therapeutic hypothermia for these patients.
- 11 October 2024
- Published by Giresun Training and Research Hospital in Cerasus Journal of Medicine
- Vol. 1 (3) , 190-194
Clinical outcomes of myelomeningocele infants without antenatal surgery: Mortality and morbidity in a tertiary ICU setting
Clinical Outcomes of Meningomyelocele Infants Without Antenatal Surgery: Mortality and Morbidity in a Tertiary ICU Setting Objective To investigate the early clinical outcomes of infants with meningomyelocele Material and methods We included infants with meningomyelocele who had undergone treatment in our tertiary neonatal intensive care unit. We included all patients with meningomyelocele between 2016-2023. We retrospectively recorded data and assessed perinatal history, morbidity, and mortality status. A p-value of
- 11 October 2024
- Published by Giresun Training and Research Hospital in Cerasus Journal of Medicine
- Vol. 1 (3) , 190-194
Clinical outcomes of myelomeningocele infants without antenatal surgery: Mortality and morbidity in a tertiary ICU setting
Clinical Outcomes of Meningomyelocele Infants Without Antenatal Surgery: Mortality and Morbidity in a Tertiary ICU Setting Objective To investigate the early clinical outcomes of infants with meningomyelocele Material and methods We included infants with meningomyelocele who had undergone treatment in our tertiary neonatal intensive care unit. We included all patients with meningomyelocele between 2016-2023. We retrospectively recorded data and assessed perinatal history, morbidity, and mortality status. A p-value of
- Open Access
- 18 March 2024
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 34 (2)
Severe Gastrointestinal Complications After IVIG Infusion in Newborns: A Two-Center Study and Literature Review
Background: There are several studies regarding perforations after intravenous immunoglobulin (IVIG) infusion; however, the risk factors are not defined yet. Objectives: The present study aimed to investigate gastrointestinal complications in newborns regarding the reported immunoglobulin A (IgA) levels in IVIG preparations. Methods: This retrospective chart review was conducted on term newborns who received IVIG therapy in two centers in Istanbul. The study included patients with IVIG-associated gastrointestinal bleedings, necrotizing enterocolitis (NEC), and intra-abdominal perforations without any underlying diseases and recorded demographic data (gestational age, birth weight, and gender) and the IgA levels in the IVIG preparations. Infants born below 35 gestational weeks were excluded as they were more likely to have NEC. Results: A total of 71 patients received IVIG therapy, and 15.5% (n = 11) developed major gastrointestinal system (GIS) complications. A total of 36 patients were born ≥ 35 gestational weeks, and gastrointestinal perforation or bleeding occurred in 22.2% (n = 8) of these patients. Two patients died before surgery due to aggressive disease progression. None of these patients had any gastrointestinal symptoms before IVIG therapy or any predisposing factors for gastrointestinal perforation. All patients were on spontaneous breathing and enteral feeding without intolerance. The IgA level content of the IVIG preparations was related to the major GIS complications with strong evidence, and the safe threshold resulted in 14 mg/dL in receiver operating characteristic (ROC) analysis in the present study group. Conclusions: Higher IgA levels in IVIG preparations might be a risk factor for gastrointestinal perforation and bleeding in term newborns. Clinicians should be aware of this potential complication when using IVIG therapy in term newborns and closely monitor for signs and symptoms of major gastrointestinal complications.
- 18 March 2024
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 34 (2)
Open AccessSevere Gastrointestinal Complications After IVIG Infusion in Newborns: A Two-Center Study and Literature Review
Background: There are several studies regarding perforations after intravenous immunoglobulin (IVIG) infusion; however, the risk factors are not defined yet. Objectives: The present study aimed to investigate gastrointestinal complications in newborns regarding the reported immunoglobulin A (IgA) levels in IVIG preparations. Methods: This retrospective chart review was conducted on term newborns who received IVIG therapy in two centers in Istanbul. The study included patients with IVIG-associated gastrointestinal bleedings, necrotizing enterocolitis (NEC), and intra-abdominal perforations without any underlying diseases and recorded demographic data (gestational age, birth weight, and gender) and the IgA levels in the IVIG preparations. Infants born below 35 gestational weeks were excluded as they were more likely to have NEC. Results: A total of 71 patients received IVIG therapy, and 15.5% (n = 11) developed major gastrointestinal system (GIS) complications. A total of 36 patients were born ≥ 35 gestational weeks, and gastrointestinal perforation or bleeding occurred in 22.2% (n = 8) of these patients. Two patients died before surgery due to aggressive disease progression. None of these patients had any gastrointestinal symptoms before IVIG therapy or any predisposing factors for gastrointestinal perforation. All patients were on spontaneous breathing and enteral feeding without intolerance. The IgA level content of the IVIG preparations was related to the major GIS complications with strong evidence, and the safe threshold resulted in 14 mg/dL in receiver operating characteristic (ROC) analysis in the present study group. Conclusions: Higher IgA levels in IVIG preparations might be a risk factor for gastrointestinal perforation and bleeding in term newborns. Clinicians should be aware of this potential complication when using IVIG therapy in term newborns and closely monitor for signs and symptoms of major gastrointestinal complications.
- Open Access
- 30 January 2024
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 4 (1) , 1-6
Is medical therapy succesful in hemodynamically significant patent ductus treatment in term newborns?
Aim: To investigate the clinical success of medical patent ductus arteriosus closure treatment for hemodynamically significant patent ductus arteriosus in term babies. Methods: Our study included patients treated in two neonatal intensive care units with hemodynamically significant patent ductus arteriosus after the 3rd postnatal day and administered medical patent ductus arteriosus closure treatment (ibuprofen and paracetamol) at the discretion of the pediatric cardiologists while awaiting referral for surgical closure treatment. Our retrospective analysis included anthropometric measurements at birth, the day treatment started postnatally, and other existing clinical conditions that might influence the prognosis of patent ductus arteriosus. Then, treatment success was evaluated by echocardiographic results. Results: We included all ten patients diagnosed with hemodynamically significant patent ductus arteriosus and administered medical treatment with a mean gestational age at birth of 38.4 ± 1.21 weeks, and median birth weight of 3125 grams (3005-3200). We started medical closure treatment at mean postnatal 11.6 ± 4.9 days with ibuprofen (70%, n=7) or paracetamol (30%, n=3). 40% (n=4) of the infants had complete closure, 20% (n=2) became asymptomatic, and 10% (n=1) underwent surgical ligation. 30% (n=3) of patients died due to different complications during surgical preparation. As we defined treatment success as complete or partial closure and compared paracetamol and ibuprofen success, there was no statistically significant difference between them (p=0.5). Conclusion: Medical closure treatment might be effective in the presence of hemodynamically significant patent ductus arteriosus in term infants. There was no statistical superiority of paracetamol or ibuprofen treatments over each other in terms of treatment success.
- 30 January 2024
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 4 (1) , 1-6
Open AccessIs medical therapy succesful in hemodynamically significant patent ductus treatment in term newborns?
Aim: To investigate the clinical success of medical patent ductus arteriosus closure treatment for hemodynamically significant patent ductus arteriosus in term babies. Methods: Our study included patients treated in two neonatal intensive care units with hemodynamically significant patent ductus arteriosus after the 3rd postnatal day and administered medical patent ductus arteriosus closure treatment (ibuprofen and paracetamol) at the discretion of the pediatric cardiologists while awaiting referral for surgical closure treatment. Our retrospective analysis included anthropometric measurements at birth, the day treatment started postnatally, and other existing clinical conditions that might influence the prognosis of patent ductus arteriosus. Then, treatment success was evaluated by echocardiographic results. Results: We included all ten patients diagnosed with hemodynamically significant patent ductus arteriosus and administered medical treatment with a mean gestational age at birth of 38.4 ± 1.21 weeks, and median birth weight of 3125 grams (3005-3200). We started medical closure treatment at mean postnatal 11.6 ± 4.9 days with ibuprofen (70%, n=7) or paracetamol (30%, n=3). 40% (n=4) of the infants had complete closure, 20% (n=2) became asymptomatic, and 10% (n=1) underwent surgical ligation. 30% (n=3) of patients died due to different complications during surgical preparation. As we defined treatment success as complete or partial closure and compared paracetamol and ibuprofen success, there was no statistically significant difference between them (p=0.5). Conclusion: Medical closure treatment might be effective in the presence of hemodynamically significant patent ductus arteriosus in term infants. There was no statistical superiority of paracetamol or ibuprofen treatments over each other in terms of treatment success.
- Open Access
- 30 January 2024
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 4 (1) , 1-6
Is medical therapy succesful in hemodynamically significant patent ductus treatment in term newborns?
Aim: To investigate the clinical success of medical patent ductus arteriosus closure treatment for hemodynamically significant patent ductus arteriosus in term babies. Methods: Our study included patients treated in two neonatal intensive care units with hemodynamically significant patent ductus arteriosus after the 3rd postnatal day and administered medical patent ductus arteriosus closure treatment (ibuprofen and paracetamol) at the discretion of the pediatric cardiologists while awaiting referral for surgical closure treatment. Our retrospective analysis included anthropometric measurements at birth, the day treatment started postnatally, and other existing clinical conditions that might influence the prognosis of patent ductus arteriosus. Then, treatment success was evaluated by echocardiographic results. Results: We included all ten patients diagnosed with hemodynamically significant patent ductus arteriosus and administered medical treatment with a mean gestational age at birth of 38.4 ± 1.21 weeks, and median birth weight of 3125 grams (3005-3200). We started medical closure treatment at mean postnatal 11.6 ± 4.9 days with ibuprofen (70%, n=7) or paracetamol (30%, n=3). 40% (n=4) of the infants had complete closure, 20% (n=2) became asymptomatic, and 10% (n=1) underwent surgical ligation. 30% (n=3) of patients died due to different complications during surgical preparation. As we defined treatment success as complete or partial closure and compared paracetamol and ibuprofen success, there was no statistically significant difference between them (p=0.5). Conclusion: Medical closure treatment might be effective in the presence of hemodynamically significant patent ductus arteriosus in term infants. There was no statistical superiority of paracetamol or ibuprofen treatments over each other in terms of treatment success.
- 30 January 2024
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 4 (1) , 1-6
Open AccessIs medical therapy succesful in hemodynamically significant patent ductus treatment in term newborns?
Aim: To investigate the clinical success of medical patent ductus arteriosus closure treatment for hemodynamically significant patent ductus arteriosus in term babies. Methods: Our study included patients treated in two neonatal intensive care units with hemodynamically significant patent ductus arteriosus after the 3rd postnatal day and administered medical patent ductus arteriosus closure treatment (ibuprofen and paracetamol) at the discretion of the pediatric cardiologists while awaiting referral for surgical closure treatment. Our retrospective analysis included anthropometric measurements at birth, the day treatment started postnatally, and other existing clinical conditions that might influence the prognosis of patent ductus arteriosus. Then, treatment success was evaluated by echocardiographic results. Results: We included all ten patients diagnosed with hemodynamically significant patent ductus arteriosus and administered medical treatment with a mean gestational age at birth of 38.4 ± 1.21 weeks, and median birth weight of 3125 grams (3005-3200). We started medical closure treatment at mean postnatal 11.6 ± 4.9 days with ibuprofen (70%, n=7) or paracetamol (30%, n=3). 40% (n=4) of the infants had complete closure, 20% (n=2) became asymptomatic, and 10% (n=1) underwent surgical ligation. 30% (n=3) of patients died due to different complications during surgical preparation. As we defined treatment success as complete or partial closure and compared paracetamol and ibuprofen success, there was no statistically significant difference between them (p=0.5). Conclusion: Medical closure treatment might be effective in the presence of hemodynamically significant patent ductus arteriosus in term infants. There was no statistical superiority of paracetamol or ibuprofen treatments over each other in terms of treatment success.
- 3 July 2023
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 20 (2) , 1691-1700
Türkiye'de Bir Yenidoğan Yoğun Bakım Ünitesinde Sağlık Hizmetlerine Bağlı Enfeksiyonların Özellikleri
Giriş: Sağlık hizmeti ile ilişkili enfeksiyonlar (SHİE), yenidoğan yoğun bakım ünitelerinde (YYBU) neonatal mortalite, morbidite ve sağlık bakım maliyetini artıran risklerden biridir. SHİE'lerin özellikleri farklı bölgelerde ve zaman içinde önemli ölçüde farklılık gösterdiğinden, sürekli SHİE sürveyansı, enfeksiyon kontrolü için SHİE oranlarını ve sağlık bakımıyla ilişkili patojenleri belirlemek açısından önemlidir. Gereç ve Yöntemler: Türkiye'de üçüncü basamak bir referans merkezindeki SHİE'nin özelliklerini incelemeyi amaçladık. 2011-2013 yılları arasında YYBU'ye kabul edilen tüm yenidoğanlar bu çalışmaya dahil edildi. SHİE ile ilgili bilgiler “Ulusal Hastane Enfeksiyon Gözetim Ağı” ve Hastalık Kontrol ve Önleme Merkezleri(CDC)’nin standartlarına göre toplanmıştır. Bulgular: Toplam yatan hasta sayısı 1030 idi. Bunların% 29'unda SHİE gelişti. SHİE'nin genel oranı ve yoğunluğu sırasıyla% 29.0 ve% 24.0 idi. Kan dolaşımı enfeksiyonları, SHİE 'lerin% 36.4'ü idi. En sık izole edilen mikro-organizmalar koagülaz negatif Staphylococci ve Klebsiella pneumonia idi. Ortalama metisilin direnci % 87, ESBL oranı% 79 ve VRE oranı % 40 idi. Sonuçlar: Bu çalışma, SHİE 'nin YYBU'de hala ciddi bir sorun teşkil ettiğini belirlemiştir. Sağlık bakımıyla ilişkili patojenler hakkında zamanında ve doğru epidemiyolojik bilgilerin mevcudiyeti, enfeksiyon kontrolü ve uygun ampirik antibiyotik seçimi için gereklidir.
- 3 July 2023
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 20 (2) , 1691-1700
Türkiye'de Bir Yenidoğan Yoğun Bakım Ünitesinde Sağlık Hizmetlerine Bağlı Enfeksiyonların Özellikleri
Giriş: Sağlık hizmeti ile ilişkili enfeksiyonlar (SHİE), yenidoğan yoğun bakım ünitelerinde (YYBU) neonatal mortalite, morbidite ve sağlık bakım maliyetini artıran risklerden biridir. SHİE'lerin özellikleri farklı bölgelerde ve zaman içinde önemli ölçüde farklılık gösterdiğinden, sürekli SHİE sürveyansı, enfeksiyon kontrolü için SHİE oranlarını ve sağlık bakımıyla ilişkili patojenleri belirlemek açısından önemlidir. Gereç ve Yöntemler: Türkiye'de üçüncü basamak bir referans merkezindeki SHİE'nin özelliklerini incelemeyi amaçladık. 2011-2013 yılları arasında YYBU'ye kabul edilen tüm yenidoğanlar bu çalışmaya dahil edildi. SHİE ile ilgili bilgiler “Ulusal Hastane Enfeksiyon Gözetim Ağı” ve Hastalık Kontrol ve Önleme Merkezleri(CDC)’nin standartlarına göre toplanmıştır. Bulgular: Toplam yatan hasta sayısı 1030 idi. Bunların% 29'unda SHİE gelişti. SHİE'nin genel oranı ve yoğunluğu sırasıyla% 29.0 ve% 24.0 idi. Kan dolaşımı enfeksiyonları, SHİE 'lerin% 36.4'ü idi. En sık izole edilen mikro-organizmalar koagülaz negatif Staphylococci ve Klebsiella pneumonia idi. Ortalama metisilin direnci % 87, ESBL oranı% 79 ve VRE oranı % 40 idi. Sonuçlar: Bu çalışma, SHİE 'nin YYBU'de hala ciddi bir sorun teşkil ettiğini belirlemiştir. Sağlık bakımıyla ilişkili patojenler hakkında zamanında ve doğru epidemiyolojik bilgilerin mevcudiyeti, enfeksiyon kontrolü ve uygun ampirik antibiyotik seçimi için gereklidir.
- 15 June 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (2) , 155-160
Early Clinical Outcomes of Congenital Diaphragmatic Hernia and Prognosis: A Retrospective Multicenter Study
- 15 June 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (2) , 155-160
Early Clinical Outcomes of Congenital Diaphragmatic Hernia and Prognosis: A Retrospective Multicenter Study
- 31 May 2023
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (5) , 235-240
Nutritional Status of Pediatric Patients With Acute Lymphoblastic Leukemia Under Chemotherapy: A Pilot Longitudinal Study
Background: The study investigates the nutritional status in children with acute lymphoblastic leukemia (ALL) during chemotherapy treatment because nourishment is substantial, as much as chemotherapy in children with malignant diseases. Material and Method: We enrolled 17 children with ALL (between 1 to 16 year-old, mean age 6.03 ± 4.04 y) from 5 different centers in Istanbul between September 2013 and May 2014. Anthropometric data, prealbumin, B12, and folate levels were assessed, at diagnosis, after the induction phase of chemotherapy, and before maintenance phases of chemotherapy in a longitudinal and prospective study. Results: Patients remarkably lost weight at the end of the induction phase (P=0.064) and regained this loss before maintenance chemotherapy (P=0.001). At the end of induction chemotherapy serum prealbumin level (P=0.002), weight for height ratios (P=0.016), weight for age ratios (P=0.019) significantly decreased. From the end of the induction phase to the beginning of maintenance chemotherapy, weight (P=0.001) and weight for age (P=0.017) significantly, and weight for height were remarkably elevated (P=0.076). At the end of the induction phase, serum prealbumin levels were significantly lower (P=0.048) and below laboratory reference values (P=0.009) in children younger than 60 months compared with those older. Serum folate levels increased from the end of the induction phase to the beginning of the maintenance phase (P=0.025). Serum vitamin B12 levels did not alter significantly. Conclusion: There is malnutrition risk at the end of the induction phase of the ALL-BFM chemotherapy regimen; therefore, clinicians should follow up on nutrition closely, especially in under 5-year-old patients. However, before the beginning of the maintenance phase, children start to gain weight, and obesity risk occurs. Thus, further studies are needed to evaluate nutritional status during childhood ALL chemotherapy.
- 31 May 2023
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (5) , 235-240
Nutritional Status of Pediatric Patients With Acute Lymphoblastic Leukemia Under Chemotherapy: A Pilot Longitudinal Study
Background: The study investigates the nutritional status in children with acute lymphoblastic leukemia (ALL) during chemotherapy treatment because nourishment is substantial, as much as chemotherapy in children with malignant diseases. Material and Method: We enrolled 17 children with ALL (between 1 to 16 year-old, mean age 6.03 ± 4.04 y) from 5 different centers in Istanbul between September 2013 and May 2014. Anthropometric data, prealbumin, B12, and folate levels were assessed, at diagnosis, after the induction phase of chemotherapy, and before maintenance phases of chemotherapy in a longitudinal and prospective study. Results: Patients remarkably lost weight at the end of the induction phase (P=0.064) and regained this loss before maintenance chemotherapy (P=0.001). At the end of induction chemotherapy serum prealbumin level (P=0.002), weight for height ratios (P=0.016), weight for age ratios (P=0.019) significantly decreased. From the end of the induction phase to the beginning of maintenance chemotherapy, weight (P=0.001) and weight for age (P=0.017) significantly, and weight for height were remarkably elevated (P=0.076). At the end of the induction phase, serum prealbumin levels were significantly lower (P=0.048) and below laboratory reference values (P=0.009) in children younger than 60 months compared with those older. Serum folate levels increased from the end of the induction phase to the beginning of the maintenance phase (P=0.025). Serum vitamin B12 levels did not alter significantly. Conclusion: There is malnutrition risk at the end of the induction phase of the ALL-BFM chemotherapy regimen; therefore, clinicians should follow up on nutrition closely, especially in under 5-year-old patients. However, before the beginning of the maintenance phase, children start to gain weight, and obesity risk occurs. Thus, further studies are needed to evaluate nutritional status during childhood ALL chemotherapy.
- 13 January 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (5) , e1924-e1931
Steroid Hormone Profiles and Molecular Diagnostic Tools in Pediatric Patients With non-CAH Primary Adrenal Insufficiency
Context There is a significant challenge of attributing specific diagnoses to patients with primary adrenal insufficiency of unknown etiology other than congenital adrenal hyperplasia (non-CAH PAI). Specific diagnoses per se may guide personalized treatment or may illuminate pathophysiology. Objective This work aimed to investigate the efficacy of steroid hormone profiles and high-throughput sequencing methods in establishing the etiology in non-CAH PAI of unknown origin. Methods Pediatric patients with non-CAH PAI whose etiology could not be established by clinical and biochemical characteristics were enrolled. Genetic analysis was performed using targeted-gene panel sequencing (TPS) and whole-exome sequencing (WES). Plasma adrenal steroids were quantified by liquid chromatography–mass spectrometry and compared to that of controls. This study comprised 18 pediatric endocrinology clinics with 41 patients (17 girls, median age: 3 mo, range: 0-8 y) with non-CAH PAI of unknown etiology. Results A genetic diagnosis was obtained in 29 (70.7%) patients by TPS. Further molecular diagnosis could not be achieved by WES. Compared to a healthy control group, patients showed lower steroid concentrations, most statistically significantly in cortisone, cortisol, and corticosterone (P < .0001, area under the receiver operating characteristic curve: .96, .88, and .87, respectively). Plasma cortisol of less than 4 ng/mL, cortisone of less than 11 ng/mL, and corticosterone of less than 0.11 ng/mL had a greater than 95% specificity to ensure the diagnosis of non-CAH PAI of unknown etiology. Conclusion Steroid hormone profiles are highly sensitive for the diagnosis of non-CAH PAI of unknown etiology, but they are unlikely to point to a specific molecular diagnosis. TPS is an optimal approach in the molecular diagnosis of these patients with high efficacy, whereas little additional benefit is expected from WES.
- 13 January 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (5) , e1924-e1931
Steroid Hormone Profiles and Molecular Diagnostic Tools in Pediatric Patients With non-CAH Primary Adrenal Insufficiency
Context There is a significant challenge of attributing specific diagnoses to patients with primary adrenal insufficiency of unknown etiology other than congenital adrenal hyperplasia (non-CAH PAI). Specific diagnoses per se may guide personalized treatment or may illuminate pathophysiology. Objective This work aimed to investigate the efficacy of steroid hormone profiles and high-throughput sequencing methods in establishing the etiology in non-CAH PAI of unknown origin. Methods Pediatric patients with non-CAH PAI whose etiology could not be established by clinical and biochemical characteristics were enrolled. Genetic analysis was performed using targeted-gene panel sequencing (TPS) and whole-exome sequencing (WES). Plasma adrenal steroids were quantified by liquid chromatography–mass spectrometry and compared to that of controls. This study comprised 18 pediatric endocrinology clinics with 41 patients (17 girls, median age: 3 mo, range: 0-8 y) with non-CAH PAI of unknown etiology. Results A genetic diagnosis was obtained in 29 (70.7%) patients by TPS. Further molecular diagnosis could not be achieved by WES. Compared to a healthy control group, patients showed lower steroid concentrations, most statistically significantly in cortisone, cortisol, and corticosterone (P < .0001, area under the receiver operating characteristic curve: .96, .88, and .87, respectively). Plasma cortisol of less than 4 ng/mL, cortisone of less than 11 ng/mL, and corticosterone of less than 0.11 ng/mL had a greater than 95% specificity to ensure the diagnosis of non-CAH PAI of unknown etiology. Conclusion Steroid hormone profiles are highly sensitive for the diagnosis of non-CAH PAI of unknown etiology, but they are unlikely to point to a specific molecular diagnosis. TPS is an optimal approach in the molecular diagnosis of these patients with high efficacy, whereas little additional benefit is expected from WES.